Please use this identifier to cite or link to this item:
|Title:||Pharmacologically induced angiogenesis in transgenic zebrafish|
|Authors:||Raghunath, M. |
Sy Wong, Y.
Prolyl hydroxylase inhibitors
|Citation:||Raghunath, M., Sy Wong, Y., Farooq, M., Ge, R. (2009-01-23). Pharmacologically induced angiogenesis in transgenic zebrafish. Biochemical and Biophysical Research Communications 378 (4) : 766-771. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bbrc.2008.11.127|
|Abstract:||The rapid vascularisation of biomaterials and engineered tissue after implantation is a current unmet need. To this end, we explored the pharmacological option of inducing neovascularisation using compounds that inhibit hypoxia-induced factor-1α prolyl hydroxylase. This stabilises hypoxia inducible factor-1α and therefore de-repress the transcription of various angiogenic genes. In the quest for a small vertebrate model allowing for in vivo screening we exposed (TG(Fli1:EGFP)) transgenic zebrafish embryos exhibiting fluorescent blood vessels to hydralazine hydrochloride and 2,4-pyridine dicarboxylic acid from 6 hpf to 72 hpf by immersion. Live observation of embryos revealed that the substances induced formation of ectopic blood vessels in the subintestinal vessel basket. We confirmed the HIF-stabilising effects biochemically in human fibroblasts and with an in vitro angiogenesis fibroblast/HUVEC co-culture model. Cross-inhibition of collagen prolyl hydroxylase was confirmed by reduced collagen secretion by fibroblasts and reduced collagen content of zebrafish embryos. © 2008 Elsevier Inc. All rights reserved.|
|Source Title:||Biochemical and Biophysical Research Communications|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 19, 2018
WEB OF SCIENCETM
checked on Jun 25, 2018
checked on Jun 29, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.